Pricing & Reimbursement Impact Analysis
Model the impact before policy moves the market.
A defensible framework for modeling pricing and reimbursement impact on pharma forecasts and launch strategy — across geographies and policy scenarios.
"How would pricing or reimbursement change reshape our launch and forecast?"
Pricing and reimbursement changes typically move 15–30% of forecast revenue. Defensible analysis models geo-by-geo with explicit policy-scenario drivers.
Pricing and reimbursement scenarios materially reshape pharma forecasts. The teams that model them explicitly — by geography, by scenario — make defensible launch and brand decisions that reactive teams cannot.
What we’re seeing in the data.
IRA changes US economics
Inflation Reduction Act negotiation directly resets revenue arc for selected drugs.
NICE leads EU price erosion
NICE TA decisions cascade through EU reference pricing.
Access timing dominates revenue arc
Time to formulary > headline price.
Indication-based pricing complicates
Per-indication pricing in EU creates segmented revenue.
How to think about it.
-
01
Map current price/access
List, net, payer placement.
-
02
Define scenario set
IRA, NICE, EU HTA reform, country-specific.
-
03
Model revenue impact
Per scenario, per geography.
-
04
Score launch sequence
Optimize which countries first under each scenario.
-
05
Track policy signal
Live policy-watch system.
What separates a good answer from a defensible one.
EU prices interconnect.
Net price often opaque.
High OOP affects realized adoption.
Reimbursement ≠ utilization.
Where the signal comes from.
Common questions.
How big is IRA impact on a typical drug?
For selected drugs, 30–50% revenue compression in the year of negotiated price.
Can you forecast HTA outcomes?
Yes — pattern-based prediction using prior NICE / G-BA decisions has improved markedly.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist